This viewpoint highlights tariff weaknesses in revitalizing drug manufacturing in the US, suggesting moderate tariff implementation could enhance industrial policy.
This Viewpoint discusses the reasons that drug manufacturing is leaving the US; highlights the weaknesses of tariffs as currently implemented for bringing it back; and calls for the moderate implementation of tariffs as one component of industrial policy and the reinvestment of tariff revenues in pharmaceutical innovation.
No takes yet. Share an insight, caveat, or question.
James C. Robinson (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: